19 completed, 4 terminated, 3 recruiting, 1 suspended. 29 Phase 2, 16 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 29 | Completed 19, Terminated 4, Recruiting 3, Suspended 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 16 | Completed 10, Terminated 4, Recruiting 1, Suspended 1 |
Follow Tumors: new trials by email Literature Review of Tumors trials Research Report on Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HP Pyruvate MRI in Cancers Hyperpolarized 13C-Pyruvate - Image, Warburg Effect | Phase 1 / Phase 2 | Recruiting | University of Maryland, Baltimore | 25 | 2024-06-24 | 2025-09-22 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) nab-sirolimus - Tumor, Tumor, Solid | Phase 2 | Completed | Aadi Bioscience, Inc. | 128 | 2022-03-10 | 2026-10-28 |
| CDK4/6 Tumor, Abemaciclib, Paclitaxel abemaciclib+paclitaxel - Tumors | Phase 1 / Phase 2 | Completed | Yonsei University | 30 | 2021-02-25 | 2024-12-18 |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling Alectinib, Atezolizumab, Avelumab - Cancer, Tumors | Phase 2 | Recruiting | Ulrik Lassen | 300 | 2020-08-24 | 2025-07-25 |
| A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors ASP1650 - Incurable Platinum Refractory Germ Cell Tumors, Tumors | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 19 | 2019-03-19 | 2024-11-13 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
| The Drug Rediscovery Protocol (DRUP Trial) Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors | Phase 2 | Recruiting | The Netherlands Cancer Institute | 1550 | 2016-08-01 | 2024-01-24 |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors surufatinib - Tumors | Phase 1 / Phase 2 | Completed | Hutchmed | 130 | 2015-11-01 | 2024-07-10 |
| A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors Lenvatinib, Pembrolizumab - Tumors | Phase 1 / Phase 2 | Completed | Eisai Inc. | 357 | 2015-07-22 | 2023-07-20 |
| A Study of Atezolizumab in Advanced Solid Tumors Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody - Tumors | Phase 2 | Completed | Hoffmann-La Roche | 474 | 2015-07-16 | 2021-06-04 |
| Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma Lenvatinib, Ifosfamide, Etoposide - Tumors, Solid Malignant Tumors | Phase 1 / Phase 2 | Completed | Eisai Limited | 117 | 2014-12-29 | 2023-07-11 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors nab-paclitaxel - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Celgene | 107 | 2013-12-04 | 2019-12-27 |
| Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors APS001F, Flucytosine (5-FC), 10% maltose - Tumors, Neoplasms | Phase 1 / Phase 2 | Suspended | Anaeropharma Science, Inc. | 75 | 2012-09-01 | 2021-05-12 |
| Kypho-IORT: Intraoperative Radiotherapy During Kyphoplasty for Spinal Metastases intraoperative radiotherapy - Tumors | Phase 2 | Completed | Universitätsmedizin Mannheim | 18 | 2011-01-01 | 2022-07-22 |
| A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer Fosbretabulin, Carboplatin, Paclitaxel - Tumors | Phase 2 | Completed | Mateon Therapeutics | 63 | 2008-03-01 | 2015-02-09 |
| PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Panitumumab - Cancer, Carcinoma | Phase 2 | Completed | Amgen | 52 | 2007-10-30 | 2022-10-05 |
| An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors YM 155, Docetaxel, Prednisone - Prostate Cancer, Tumors | Phase 1 / Phase 2 | Completed | Astellas Pharma Inc | 32 | 2007-05-01 | 2015-08-13 |
| Oral Topotecan to Treat Recurrent or Persistent Solid Tumors Oral Topotecan - Tumors | Phase 1 / Phase 2 | Completed | Accelerated Community Oncology Research Network | 26 | 2006-11-01 | 2013-07-22 |
| A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine MGCD0103, Gemcitabine - Tumors | Phase 1 / Phase 2 | Completed | Mirati Therapeutics Inc. | 47 | 2006-09-01 | 2015-07-01 |
| Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy Filgrastim, Pegfilgrastim - Hematological Neoplasms, Tumors | Phase 2 | Completed | Armando Santoro, MD | 80 | 2006-09-01 | 2013-07-01 |
Showing 20 of 29. Sign in to see all of them.
Neoplasms (29) · Neoplasm Metastasis (4) · Lung Neoplasms (2) · Osteosarcoma (2) · Sarcoma (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoid Tumor (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Dermatofibrosarcoma (1) · Esophageal Neoplasms (1) · Fibrosarcoma (1)
Neoplasms by Histologic Type (7) · Neoplasms by Site (7) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Neoplastic Processes (5) · Neoplasms, Glandular and Epithelial (4) · Hemic and Lymphatic Diseases (3) · Neoplasms, Connective and Soft Tissue (3) · Carcinoma (2) · Cardiovascular Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Genital Diseases (2)
Carboplatin (3) · atezolizumab (3) · lenvatinib (3) · Axitinib (2) · Bevacizumab (2) · Capecitabine (2) · Erlotinib Hydrochloride (2) · HhAntag691 (2) · Ipilimumab (2) · Nivolumab (2) · Paclitaxel (2) · Panitumumab (2) · Trastuzumab (2) · Vemurafenib (2) · alectinib (2)
Bristol-Myers Squibb (2) · Hadassah Medical Organization (2) · AEterna Zentaris (1) · AHS Cancer Control Alberta (1) · Aadi Bioscience, Inc. (1) · Accelerated Community Oncology Research Network (1) · Amgen (1) · Anaeropharma Science, Inc. (1) · Armando Santoro, MD (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1) · AstraZeneca (1) · Celgene (1) · Eisai Inc. (1) · Eisai Limited (1)
United States (18) · Canada (7) · Italy (5) · Spain (5) · France (4) · Germany (4) · United Kingdom (4) · Netherlands (3) · Switzerland (3) · Denmark (2) · Israel (2) · Norway (2) · South Korea (2) · Austria (1) · Brazil (1)
Shimon Slavin, MD (2) · Armando Santoro, MD (1) · E.E. Voest, prof. (1) · Gregory Reid, MSc, MBA (1) · Ileana Elias, M.D. (1) · Jai Balkissoon, MD, FACS (1) · Jane Robertson, MD (1) · Marjo Hahka-Kemppinen, MD, PhD (1) · Michael Sawyer, MD (1) · Reuven Or, MD (1)
PMID 31401903, PMID 20007996, PMID 28962909, PMID 30922731, PMID 31961766, PMID 32167863, PMID 32554315, PMID 33183307, PMID 34039647, PMID 34143969, PMID 34416158, PMID 34416160, PMID 34562750, PMID 35086719, PMID 35305400, PMID 35598186, PMID 35759134, PMID 36608305, PMID 36814246, PMID 36870947, PMID 37074571, PMID 37424386, PMID 38242717, PMID 38630551, PMID 41986720
2017 (2), 2015 (1)